Literature DB >> 6411762

A three-year study of nosocomial infections associated with Pseudomonas aeruginosa.

R J Sherertz, F A Sarubbi.   

Abstract

During a 3-year study period in a university teaching hospital, 417 nosocomial infections associated with Pseudomonas aeruginosa were documented in 321 patients. The overall rate of P. aeruginosa nosocomial infection was 5.3 cases per 1,000 patients. Residence on the surgery or medicine service, advanced patient age, and exposure to the burn, surgery, or medicine intensive care units correlated with higher rates of infection. The most common sites for P. aeruginosa infection were the lower respiratory tract, urinary tract, blood stream, and surgical wounds. Nosocomial P. aeruginosa lower respiratory tract and blood stream infections were significantly associated with exposure to certain intensive care units, whereas P. aeruginosa urinary tract infections more commonly occurred on the neurology and neurosurgery services. Results of live antigen serotyping showed that serotype 6 was most common, followed by serotypes 1 and 11. Serotype 6 correlated with resistance to carbenicillin, gentamicin, and tobramycin, and serotype 11 correlated with resistance to carbenicillin. Two-thirds of the isolates tested were sensitive to carbenicillin, gentamicin, and tobramycin, but 13.2% were resistant to all three of these drugs. P. aeruginosa isolates resistant to all three drugs were associated with urinary tract infections.

Entities:  

Mesh:

Year:  1983        PMID: 6411762      PMCID: PMC270761          DOI: 10.1128/jcm.18.1.160-164.1983

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  11 in total

1.  Pseudomonas pneumonia. A retrospective study of 36 cases.

Authors:  J E Pennington; H Y Reynolds; P P Carbone
Journal:  Am J Med       Date:  1973-08       Impact factor: 4.965

2.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

3.  Epidemiological studies of Pseudomonas species in patients with leukemia.

Authors:  G P Bodey
Journal:  Am J Med Sci       Date:  1970-08       Impact factor: 2.378

4.  Clinical and epidemiological correlates of Pseudomonas typing.

Authors:  R S Baltimore; A S Dobek; F R Stark; M S Artenstein
Journal:  J Infect Dis       Date:  1974-11       Impact factor: 5.226

5.  Nosocomial infections due to Pseudomonas.

Authors:  J V Bennett
Journal:  J Infect Dis       Date:  1974-11       Impact factor: 5.226

6.  Pseudomonas bacteremia. Review of 108 cases.

Authors:  M R Flick; L E Cluff
Journal:  Am J Med       Date:  1976-04       Impact factor: 4.965

Review 7.  Gram-negative bacteremia. III. Reassessment of etiology, epidemiology and ecology in 612 patients.

Authors:  B E Kreger; D E Craven; P C Carling; W R McCabe
Journal:  Am J Med       Date:  1980-03       Impact factor: 4.965

8.  Serological typing of Pseudomonas aeruginosa: use of commercial antisera and live antigens.

Authors:  C D Brokopp; R Gomez-Lus; J J Farmer
Journal:  J Clin Microbiol       Date:  1977-06       Impact factor: 5.948

9.  Hospital outbreaks caused by Pseudomonas aeruginosa: importance of serogroup O11.

Authors:  J J Farmer; R A Weinstein; C H Zierdt; C D Brokopp
Journal:  J Clin Microbiol       Date:  1982-08       Impact factor: 5.948

10.  Nursery outbreak of Pseudomonas aeruginosa: epidemiological conclusions from five different typing methods.

Authors:  R A Bobo; E J Newton; L F Jones; L H Farmer; J J Farmer
Journal:  Appl Microbiol       Date:  1973-03
View more
  14 in total

1.  EVALUATION OF HOSPITAL ACQUIRED PSEUDOMONAS INFECTION IN PARAPLEGIC AND ORTHOPAEDIC CASES.

Authors:  K K Lahiri
Journal:  Med J Armed Forces India       Date:  2017-06-26

2.  Genome fingerprinting by pulsed-field gel electrophoresis and ribotyping to differentiate Pseudomonas aeruginosa serotype O11 strains.

Authors:  C L Poh; C C Yeo; L Tay
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-09       Impact factor: 3.267

3.  MexT regulates the type III secretion system through MexS and PtrC in Pseudomonas aeruginosa.

Authors:  Yongxin Jin; Hongjiang Yang; Mingqiang Qiao; Shouguang Jin
Journal:  J Bacteriol       Date:  2010-11-12       Impact factor: 3.490

4.  In vitro activity of carumonam (RO 17-2301) and twelve other antimicrobials against clinical isolates of Pseudomonas aeruginosa.

Authors:  U Vurma-Rapp; F H Kayser
Journal:  Eur J Clin Microbiol       Date:  1986-06       Impact factor: 3.267

5.  Antibiotic susceptibility of clinical isolates of Pseudomonas aeruginosa.

Authors:  C Cervantes-Vega; J Chavez; M G Rodriguez
Journal:  Antonie Van Leeuwenhoek       Date:  1986       Impact factor: 2.271

6.  Trends in nosocomial bloodstream infections following health care restructuring in Alberta between 1999 and 2005.

Authors:  Mao-Cheng Lee; Lynora Saxinger; Sarah E Forgie; Geoffrey Taylor
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

7.  Revised pyocin typing method for Pseudomonas aeruginosa.

Authors:  J A Fyfe; G Harris; J R Govan
Journal:  J Clin Microbiol       Date:  1984-07       Impact factor: 5.948

8.  Human monoclonal antibodies that protect mice against challenge with Pseudomonas aeruginosa.

Authors:  H J Zweerink; M C Gammon; C F Hutchison; J J Jackson; D Lombardo; K M Miner; J M Puckett; T J Sewell; N H Sigal
Journal:  Infect Immun       Date:  1988-08       Impact factor: 3.441

9.  Detection of point mutations associated with antibiotic resistance in Pseudomonas aeruginosa.

Authors:  Neda Gorgani; Scott Ahlbrand; Andrew Patterson; Nader Pourmand
Journal:  Int J Antimicrob Agents       Date:  2009-08-04       Impact factor: 5.283

10.  Surface-grafted polysarcosine as a peptoid antifouling polymer brush.

Authors:  King Hang Aaron Lau; Chunlai Ren; Tadas S Sileika; Sung Hyun Park; Igal Szleifer; Phillip B Messersmith
Journal:  Langmuir       Date:  2012-11-12       Impact factor: 3.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.